Log in
Enquire now
‌

US Patent 7803981 Transgenic ungulates capable of human antibody production

Patent 7803981 was granted and assigned to Kyowa Hakko Kirin on September, 2010 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Current Assignee
Kyowa Hakko Kirin
Kyowa Hakko Kirin
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
7803981
Date of Patent
September 28, 2010
Patent Application Number
11820768
Date Filed
June 20, 2007
Patent Citations Received
‌
US Patent 11975066 Ungulate-derived polyclonal immunoglobulin specific for coronavirus protein and uses thereof
0
Patent Primary Examiner
‌
Deborah Crouch
Patent abstract

The invention features novel methods for the production of large quantities of xenogenous antibodies, such as human antibodies. Preferably, this result is effected by inactivation of IgM heavy chain expression and, optionally, by inactivation of Ig light chain expression, and by the further introduction of an artificial chromosome which results in the expression of xenogenous antibodies (e.g., non-bovine antibodies), preferably human antibodies.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 7803981 Transgenic ungulates capable of human antibody production

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.